Soft Contact Lenses for Near-sightedness
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate and compare two types of soft contact lenses, Biomedics 1 Day Extra Sphere and Clariti 1 Day Sphere, for individuals with near-sightedness. Participants will try each lens for a short period to determine which performs better in comfort and vision clarity. The trial seeks individuals who regularly wear soft contact lenses and have a prescription between -1.00 and -6.00 for each eye. Those who consistently have difficulty seeing distant objects clearly and are accustomed to wearing contacts might be a good fit for this study. As an unphased trial, it offers the opportunity to contribute to research that could enhance contact lens options for people with near-sightedness.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are using any medications that would interfere with contact lens use, you may not be eligible to participate.
What prior data suggests that these soft contact lenses are safe for near-sightedness?
Research has shown that both Biomedics 1 Day Extra Sphere and Clariti 1 Day Sphere contact lenses are generally safe for use. These lenses are approved for daily wear, indicating a strong safety record.
The Biomedics 1 Day Extra Sphere, made from ocufilcon D, is designed for nearsighted individuals and is well-tolerated. Studies indicate it provides clear vision without major side effects.
Clariti 1 Day Sphere, made from somofilcon A, allows more oxygen to reach the eye, promoting eye health and comfort. It also offers UV protection, adding extra safety.
Both lenses are disposable and intended for one-day use, reducing the risk of infection and other issues. Users typically report good comfort and clear vision with few negative effects.12345Why are researchers excited about this trial?
Unlike traditional contact lenses for near-sightedness, which often focus solely on correcting vision, the lenses being studied, Biomedics 1 Day Extra Sphere and Clariti 1 Day Sphere, offer unique material compositions. Lens 1 uses ocufilcon D, a hydrogel material known for its comfort, while Lens 2 utilizes somofilcon A, a silicone hydrogel that allows more oxygen to reach the eye, potentially enhancing eye health and comfort over prolonged use. Researchers are excited because these materials could provide better comfort and eye health benefits compared to conventional daily lenses, making it easier for people with near-sightedness to maintain eye health while enjoying clear vision.
What evidence suggests that this trial's treatments could be effective for near-sightedness?
In this trial, participants will test two types of soft contact lenses for near-sightedness. Research has shown that Biomedics 1 Day Extra Sphere contact lenses effectively correct near-sightedness, a condition where distant objects appear blurry. These lenses improve vision by properly focusing light in the eyes. Clariti 1 Day Sphere lenses, another option in this trial, have also been found to slow the progression of near-sightedness. Specifically, studies showed they reduced vision decline by up to 59% over three years. Both types of lenses are designed for comfort and effectiveness, with users reporting good vision correction and manageable side effects.36789
Who Is on the Research Team?
Lyndon Jones, PhD FCOptom
Principal Investigator
Centre for Ocular Research and Education
Are You a Good Fit for This Trial?
This trial is for adults over 18 who already use soft contact lenses and have mild to moderate near-sightedness, with prescriptions between -1.00DS to -6.00DS and astigmatism up to -1.00DC in each eye. Participants must be able to see clearly with the study lenses and keep scheduled appointments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants will wear each type of lens for 15 minutes to evaluate comfort
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Biomedics 1 Day Extra Sphere
- Clariti 1 Day Sphere
Find a Clinic Near You
Who Is Running the Clinical Trial?
CooperVision International Limited (CVIL)
Lead Sponsor
Dr. Patrizia Cavazzoni
CooperVision International Limited (CVIL)
Chief Medical Officer
MD from Harvard Medical School
Steven Robins
CooperVision International Limited (CVIL)
President, Americas
Bachelor of Arts from Bates College, participated in Pfizer Global Leadership Program with Harvard University
Centre for Ocular Research & Education, Canada
Collaborator